Quantitative Investment Management LLC lowered its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 58.2% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 26,700 shares of the life sciences company’s stock after selling 37,200 shares during the period. Quantitative Investment Management LLC’s holdings in Illumina were worth $5,833,000 at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of the company. Fred Alger Management Inc. raised its holdings in shares of Illumina by 3.8% during the 4th quarter. Fred Alger Management Inc. now owns 582,070 shares of the life sciences company’s stock worth $127,176,000 after buying an additional 21,128 shares in the last quarter. Nomura Asset Management Co. Ltd. raised its holdings in shares of Illumina by 2.4% during the 4th quarter. Nomura Asset Management Co. Ltd. now owns 28,882 shares of the life sciences company’s stock worth $6,310,000 after buying an additional 685 shares in the last quarter. Moors & Cabot Inc. raised its holdings in shares of Illumina by 5.0% during the 4th quarter. Moors & Cabot Inc. now owns 7,876 shares of the life sciences company’s stock worth $1,723,000 after buying an additional 376 shares in the last quarter. ETRADE Capital Management LLC raised its holdings in shares of Illumina by 34.3% during the 4th quarter. ETRADE Capital Management LLC now owns 2,739 shares of the life sciences company’s stock worth $598,000 after buying an additional 699 shares in the last quarter. Finally, MML Investors Services LLC raised its holdings in shares of Illumina by 31.9% during the 4th quarter. MML Investors Services LLC now owns 1,586 shares of the life sciences company’s stock worth $347,000 after buying an additional 384 shares in the last quarter. 91.51% of the stock is owned by institutional investors.
A number of equities analysts have recently commented on ILMN shares. Wells Fargo & Co reissued a “positive” rating and set a $260.00 price target (up previously from $250.00) on shares of Illumina in a report on Tuesday, January 9th. BTIG Research started coverage on Illumina in a report on Friday, January 5th. They set a “neutral” rating for the company. Piper Jaffray Companies boosted their price target on Illumina to $274.00 and gave the stock an “overweight” rating in a report on Thursday, January 4th. Evercore ISI started coverage on Illumina in a report on Wednesday, January 3rd. They set an “outperform” rating and a $250.00 price target for the company. Finally, BidaskClub raised Illumina from a “hold” rating to a “buy” rating in a report on Saturday. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $241.39.
Illumina, Inc. (ILMN) opened at $253.17 on Tuesday. Illumina, Inc. has a fifty-two week low of $158.02 and a fifty-two week high of $254.89. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.99 and a quick ratio of 3.55. The stock has a market capitalization of $36,767.64, a PE ratio of 51.04, a price-to-earnings-growth ratio of 3.31 and a beta of 0.93.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.22. The company had revenue of $778.00 million during the quarter, compared to analysts’ expectations of $752.04 million. Illumina had a return on equity of 21.71% and a net margin of 26.56%. The business’s quarterly revenue was up 25.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.85 earnings per share. equities analysts forecast that Illumina, Inc. will post 4.59 earnings per share for the current year.
In other news, Director A Blaine Bowman sold 3,000 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $230.82, for a total value of $692,460.00. Following the completion of the sale, the director now owns 19,868 shares of the company’s stock, valued at $4,585,931.76. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Charles Dadswell sold 145 shares of the stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $224.50, for a total value of $32,552.50. Following the completion of the sale, the senior vice president now directly owns 7,411 shares of the company’s stock, valued at approximately $1,663,769.50. The disclosure for this sale can be found here. In the last three months, insiders sold 72,887 shares of company stock valued at $16,510,025. Insiders own 0.89% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This report was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://ledgergazette.com/2018/03/13/illumina-inc-ilmn-stake-decreased-by-quantitative-investment-management-llc.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.